Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

NCT00769327 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: imatinib mesylate
DRUG: nilotinib
GENETIC: cytogenetic analysis
GENETIC: fluorescence in situ hybridization
GENETIC: microarray analysis
GENETIC: mutation analysis
GENETIC: polymerase chain reaction
GENETIC: polymorphism analysis
OTHER: laboratory biomarker analysis

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto